Idiopathic pulmonary fibrosis (IPF) is a devastating and often fatal disease in which excessive scar tissue builds up in the lung, causing the lungs to stiffen and lose functionality. There is no curative treatment for IPF except transplantation. Furthermore, existing treatment options for IPF are limited: only two drugs have received FDA approval to treat this disease, and both have limited efficacy and severe side effects. This project aims to explore a nanotechnology-based strategy to selectively deliver therapeutic agents to targeted locations within the fibrotic lung tissue. Recent literature has shown that inflammation plays a key role in the progression of IPF, so as a model drug payload, we chose Tofacitinib (TOFA), an anti-inflammatory drug. To enable targeted delivery, we are testing whether decorating TOFA particles with magnetic iron oxide nanoparticles (IONPs), forming “TofaBots,” can enable magnetically guided delivery of TOFA directly to regions where the drug will have the greatest effect, namely the regions where fibroblasts (the main cellular drivers of fibrosis) and scar tissue accumulate. The size and morphology of IONPs and TofaBots are characterized using dynamic light scattering (DLS) and scanning electron microscopy (SEM). Using externally applied magnetic fields, we demonstrate that TofaBots can actively penetrate biomimetic hydrogels that function as in vitro models of fibrotic lung tissue; the speed of TofaBots’ magnetically driven motion increases as the gel concentration decreases. Finally, we are actively exploring whether the motility of the nanoparticles can be enhanced by coating them with an ECM-degrading enzyme, such as collagenase. We hypothesize that more effective drug distribution at disease sites can enable more efficacious therapies for this enigmatic and devastating disease.